Monthly Archives: January 2018

A 36-year-old woman with ankylosing spondylitis (AS) and a 12 year history of moderate, extensive ulcerative colitis (UC) was evaluated for active symptoms after a 15 month hiatus. Prior therapy included mesalamine and infliximab; the latter led to cli… Continue reading →

The lymphatics are the main transport of lymph (containing fluid, macromolecules, and immunological components such as cells and cytokines) from the parenchymal tissues to the lymph nodes. Inflammation-induced lymphangiogenesis and lymphatic dysfunctio… Continue reading →

Inflammatory bowel disease (IBD) patients are at increased risk of colorectal cancer (CRC)1. Tumor initiating events in colitis-associated cancers (CACs) differ significantly from sporadic CRC2. In CACs, hyperactivity of wnt/beta-catenin signaling typi… Continue reading →

In mouse models of IBD, the tryptophan metabolizing enzyme indoleamine 2,3-dioxygenase 1 (IDO1) has been shown to limit disease severity. Our studies indicate that intestinal epithelial cells are an important source of IDO1 expression in these conditio… Continue reading →

We identified altered IL-6-induced Jak1-dependent STAT3 phosphorylation in human ileal subepithelial myofibroblasts (SEMF) of patients with stricturing Crohn’s disease. This resulted in co-localization of pSTAT3(Y705) to Rab5+ signaling endosomes alo… Continue reading →

Colorectal cancer (CRC) has long been associated with inflammatory bowel disease (IBD), thought to be due to chronic mucosal inflammation. With newer IBD treatments, the incidence of CRC is decreasing, possibly due to improved therapies or improved tre… Continue reading →

Inflammatory bowel disease (IBD) remain major clinical challenges and are currently incurable. Tumor necrosis factor (TNF) is a major therapeutic target in IBD, and TNFR1 polymorphisms have been described in IBD patients. Interleukin 10 (IL-10) recepto… Continue reading →

The recurrent and debilitating nature of Inflammatory Bowel Disease (IBD) makes affected patients ideal candidates to assess the therapeutic potential of a digital intervention for long-term patient management. HealthPROMISE is an innovative software p… Continue reading →

Anti-cytotoxic-T-lymphocyte associated antigen-4 (anti-CTLA4), and anti-programmed cell death 1 (anti-PD1) immunotherapies are considered first-line treatments for advanced melanoma. However, the use of these agents is limited by gastrointestinal toxic… Continue reading →

An expanding range of therapeutics have been approved or are under development for IBD. However, objective readouts of treatment efficacy are still lacking, often relying on partially subjective clinical endpoints (CDAI). High-dimensional mass cytometr… Continue reading →